Abstract: The present invention provides pharmaceutical compositions which include (?)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (?)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (?)-pseudoephedrine to a mammal. The (?)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

Abstract: The present invention provides stereoscopically-pure diastereomers of Formula I: In a preferred embodiment, the stereoisomers of the present invention are of Formula II, depicted below: R2, R3 and R4 are independently H, OH, OCH3, CH2OH, NHCONH2, NH2, halogen or CF3, and R1 is pyridine, or an amine which may be substituted with hydrogen, lower alkyl, lower alkylenearyl, lower alkylenephenyl, lower alkylenehydroxyphenyl, lower alkyleneamine, lower alkyleneaminoaryl, lower alkylaminohydroxyphenyl, or a similar functional group. R5 is hydrogen, hydroxyl or methyl; R6 is hydrogen, lower alkyl, lower alkylenaryl, lower alkylenephenyl, lower alkylenehydroxyphenyl, lower alkyleneamine, lower alkyleneaminoaryl, lower alkylaminohydroxyphenyl, and the like. For both Formula I and Formual II, the first carbon on the side chain progressing from the ring is preferably in the R-configuration. The second carbon atom on the side chain of Formula II, which is attached to R5, may or may not be a chiral center.

Abstract: The present invention provides stereoscopically-pure diastereomers of Formula I: 1

Abstract: The present invention provides stereoscopically-pure diastereomers of Formula I: In a preferred embodiment, the stereoisomers of the present invention are of Formula II, depicted below: R2, R3 and R4 are independently H, OH, OCH3, CH2OH, NHCONH2, NH2, halogen or CF3, and R1 is pyridine, or an amine which may be substituted with hydrogen, lower alkyl, lower alkylenearyl, lower alkylenephenyl, lower alkylenehydroxyphenyl, lower alkyleneamine, lower alkyleneaminoaryl, lower alkylaminohydroxyphenyl, or a similar functional group. R5 is hydrogen, hydroxyl or methyl; R6 is hydrogen, lower alkyl, lower alkylenaryl, lower alkylenephenyl, lower alkylenehydroxyphenyl, lower alkyleneamine, lower alkyleneaminoaryl, lower alkylaminohydroxyphenyl, and the like. For both Formula I and Formual II, the first carbon on the side chain progressing from the ring is preferably in the R-configuration.

Abstract: The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

Abstract: The present invention provides stereoscopically-pure diastereomers of Formula I: 1

Abstract: The present invention provides pharmaceutical compositions which include (−)-pseudoephedrine and a pharmaceutically acceptable carrier, wherein the (−)-pseudoephedrine is substantially-free of (+)-pseudoephedrine. In another embodiment, the present invention provides methods of relieving nasal and bronchial congestion and of inducing pupil dilation which include administering a pharmaceutically effective amount of (−)-pseudoephedrine to a mammal. The (−)-pseudoephedrine used in the present methods is substantially free of (+)-pseudoephedrine and also substantially free of side effects caused by administration of (+)-pseudoephedrine.

Abstract: A composition formulated for dose-wise delivery to a breathing passageway of a human, the composition comprising a carrier solution containing (+)naloxone and a pharmacologically effective amount of at least one adrenergic agonist, the (+)naloxone and agonist forming a mixture in the carrier. The at least one adrenergic agonist is selected from the group consisting of epinephrine, isoproterenol, albuterol, aminophylline, beclomethasone, dyphylline, flunisolide, isoetharine, metaproterenol, oxtriphylline, terbutaline, theophylline, pseudoephedrine, phenylephrine, ephedrine and norepinephrine. That composition is delivered by an atomizer means such as a liquid sprayer or inhaler to treat nasal congestion and asthmatic attacks. Further provided by the invention is a cardiovascular and respiratory stimulating composition for administration to a patient in doses, the composition comprising a pharmacologically effective concentration of (+)naloxone in a carrier solution.

Abstract: A method for treating medical patients suffering from cardiac trauma by co-administering pyruvate with a .beta.-adrenergic agonist. This method for treating cardiac trauma, such as ischemic reperfusion injury and heart failure, augments the inotropic effects of .beta.-adrenergic agents. Typical .beta.-adrenergic agonists are epinephrine, norepinephrine, dobutamine, and isoproterenol. The amount of .beta.-adrenergic agonist necessary to achieve a 50 percent increase of cardiac power is diminished five-fold when co-administered with pyruvate. Since high concentrations of agonists have many detrimental and hazardous side effects in patients, this invention would have important applications in the treatment of patients with cardiac trauma such as ischemia reperfusion injury.

Abstract: An improved device and method for plumbing a recirculating water pump into a hot water heating system, the water pump having a pair of connecting flanges on the inflow and outflow sides of the pump. The present invention includes a section of copper tubing which has one end flared, the flare preferably being at approximately right angles to the longitudinal axis of the tubing. Further, an installation flange is provided having a central hole and an inside face to be positioned against a corresponding face of a connecting flange of the recirculating water pump, the copper tubing being inserted through the central hole of the installation flange with the flared end positioned against the inside face of the installation flange. A flexible gasket, having a central opening, being positioned between the installation flange and the connecting flange of the recirculating pump. The installation flange and flexible gasket being connected to the connecting flange of the recirculating pump with bolts.